Neuland Labs FY26 Total Income ₹2,053 Crore; EBITDA ₹603 Crore
Neuland Laboratories reported FY26 total income of ₹2,053.1 crore and EBITDA of ₹603.4 crore. Q4FY26 income was ₹788.7 crore, up 134.9% YoY, with EBITDA at ₹319.4 crore, up 448.6% YoY. CEO Saharsh Davuluri noted strong business visibility and ongoing investments in Peptide Manufacturing and R&D.
The substantial year-over-year growth in key financial metrics like income, EBITDA, and PAT, along with positive management commentary on future prospects, is likely to have a significant positive impact on investor sentiment and the company's stock performance.
The company reported strong financial results with significant year-over-year growth in revenue and profits for both the quarter and the full fiscal year. Management commentary also reflects optimism about future performance and strategic investments.
Neuland Laboratories Limited announced its financial results for the fiscal year ended March 31, 2026, with total income reported at ₹2,053.1 crore and EBITDA at ₹603.4 crore. The company corrected a typographical error in its previous press release header, clarifying that the results pertain to FY26 instead of Q4FY26.
For the fourth quarter of FY26 (Q4FY26), Neuland Labs reported a significant year-over-year increase in total income to ₹788.7 crore, a 134.9% rise from ₹335.8 crore in Q4FY25. EBITDA for Q4FY26 surged by 448.6% to ₹319.4 crore from ₹58.2 crore in the same period last year. The EBITDA margin improved substantially to 40.5% from 17.3% year-over-year. Profit Before Tax (PBT) also saw a dramatic increase, rising 636.6% to ₹287.0 crore, with a PBT margin of 36.4%. Profit After Tax (PAT) grew by 666.3% to ₹212.5 crore.
Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, expressed satisfaction with the strong performance in FY26, citing good business visibility driven by commercial and near-commercial molecules. He highlighted the company's focus on execution discipline and customer satisfaction to ensure sustained growth. Investments in Peptide Manufacturing and a new R&D Centre are progressing as planned, with the business development strategy aligned to support high-quality, sustainable growth.
Neuland Laboratories Limited is a pharmaceutical manufacturer with over four decades of experience, supplying active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions to approximately 80 countries. The company has developed over 300 processes and 100 APIs, with more than 1000 regulatory filings globally.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under annual results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.